Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.31
TEVA's Cash to Debt is ranked lower than
81% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. TEVA: 0.31 )
Ranked among companies with meaningful Cash to Debt only.
TEVA' s 10-Year Cash to Debt Range
Min: 0.07  Med: 0.35 Max: N/A
Current: 0.31
Equity to Asset 0.48
TEVA's Equity to Asset is ranked lower than
71% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TEVA: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
TEVA' s 10-Year Equity to Asset Range
Min: 0.39  Med: 0.50 Max: 0.6
Current: 0.48
0.39
0.6
Interest Coverage 13.17
TEVA's Interest Coverage is ranked lower than
77% of the 370 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 933.44 vs. TEVA: 13.17 )
Ranked among companies with meaningful Interest Coverage only.
TEVA' s 10-Year Interest Coverage Range
Min: 3.6  Med: 8.08 Max: 328.25
Current: 13.17
3.6
328.25
F-Score: 8
Z-Score: 1.98
M-Score: -2.76
WACC vs ROIC
2.78%
9.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.41
TEVA's Operating margin (%) is ranked higher than
80% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. TEVA: 18.41 )
Ranked among companies with meaningful Operating margin (%) only.
TEVA' s 10-Year Operating margin (%) Range
Min: 8.12  Med: 14.85 Max: 26.78
Current: 18.41
8.12
26.78
Net-margin (%) 13.61
TEVA's Net-margin (%) is ranked higher than
76% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. TEVA: 13.61 )
Ranked among companies with meaningful Net-margin (%) only.
TEVA' s 10-Year Net-margin (%) Range
Min: 5.73  Med: 9.39 Max: 21.09
Current: 13.61
5.73
21.09
ROE (%) 11.87
TEVA's ROE (%) is ranked higher than
66% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.87 vs. TEVA: 11.87 )
Ranked among companies with meaningful ROE (%) only.
TEVA' s 10-Year ROE (%) Range
Min: 4.23  Med: 14.44 Max: 27
Current: 11.87
4.23
27
ROA (%) 5.90
TEVA's ROA (%) is ranked higher than
62% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. TEVA: 5.90 )
Ranked among companies with meaningful ROA (%) only.
TEVA' s 10-Year ROA (%) Range
Min: 2.26  Med: 6.44 Max: 13.11
Current: 5.9
2.26
13.11
ROC (Joel Greenblatt) (%) 42.19
TEVA's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.80 vs. TEVA: 42.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TEVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 13.61  Med: 26.59 Max: 49.79
Current: 42.19
13.61
49.79
Revenue Growth (3Y)(%) 4.80
TEVA's Revenue Growth (3Y)(%) is ranked lower than
54% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. TEVA: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TEVA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.8  Med: 15.60 Max: 23.4
Current: 4.8
4.8
23.4
EBITDA Growth (3Y)(%) 10.70
TEVA's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 476 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. TEVA: 10.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TEVA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.5  Med: 15.00 Max: 47.2
Current: 10.7
-10.5
47.2
EPS Growth (3Y)(%) 4.80
TEVA's EPS Growth (3Y)(%) is ranked higher than
50% of the 447 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. TEVA: 4.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TEVA' s 10-Year EPS Growth (3Y)(%) Range
Min: -25.6  Med: 15.50 Max: 69.8
Current: 4.8
-25.6
69.8
» TEVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

TEVA Guru Trades in Q2 2014

Jim Simons 504,663 sh (New)
Pioneer Investments 227,765 sh (+1178.29%)
Michael Price 500,000 sh (+28.73%)
Caxton Associates 7,200 sh (+22.03%)
Manning & Napier Advisors, Inc 264,965 sh (+14.58%)
Richard Snow 1,826,799 sh (+6.90%)
Ronald Muhlenkamp 176,855 sh (+0.81%)
First Eagle Investment 200 sh (unchged)
Tom Gayner 694,000 sh (unchged)
Steven Cohen 1,020,700 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Stanley Druckenmiller 1,241,000 sh (unchged)
John Keeley 47,435 sh (unchged)
Alan Fournier Sold Out
Ken Heebner Sold Out
Paul Tudor Jones Sold Out
Jana Partners Sold Out
Murray Stahl 15,782 sh (-4.66%)
Diamond Hill Capital 231,779 sh (-7.62%)
David Dreman 159,090 sh (-13.22%)
Jeremy Grantham 11,400 sh (-14.93%)
James Barrow 10,868,770 sh (-18.50%)
NWQ Managers 5,085,717 sh (-19.21%)
George Soros 7,273,240 sh (-29.45%)
Vanguard Health Care Fund 7,344,400 sh (-40.54%)
» More
Q3 2014

TEVA Guru Trades in Q3 2014

First Eagle Investment 1,420,580 sh (+710190.00%)
Manning & Napier Advisors, Inc 293,174 sh (+10.65%)
Diamond Hill Capital 246,377 sh (+6.30%)
John Keeley 47,710 sh (+0.58%)
Ronald Muhlenkamp 176,855 sh (unchged)
Michael Price 500,000 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Pioneer Investments 237,961 sh (unchged)
Caxton Associates Sold Out
Stanley Druckenmiller Sold Out
Murray Stahl Sold Out
Jeremy Grantham Sold Out
David Dreman 157,449 sh (-1.03%)
Richard Snow 1,796,499 sh (-1.66%)
James Barrow 10,370,353 sh (-4.59%)
NWQ Managers 4,698,117 sh (-7.62%)
George Soros 6,231,722 sh (-14.32%)
Vanguard Health Care Fund 5,362,100 sh (-26.99%)
Tom Gayner 444,000 sh (-36.02%)
Jim Simons 264,863 sh (-47.52%)
Steven Cohen 59,200 sh (-94.20%)
» More
Q4 2014

TEVA Guru Trades in Q4 2014

Charles Brandes 3,600 sh (New)
Caxton Associates 19,500 sh (New)
Louis Moore Bacon 180,000 sh (New)
Pioneer Investments 1,035,721 sh (+335.25%)
Steven Cohen 238,000 sh (+302.03%)
Jim Simons 964,663 sh (+264.21%)
First Eagle Investment 2,448,310 sh (+72.35%)
James Barrow 10,823,115 sh (+4.37%)
Richard Snow 1,856,728 sh (+3.35%)
Bernard Horn 65,600 sh (unchged)
Tom Gayner Sold Out
Manning & Napier Advisors, Inc 293,088 sh (-0.03%)
Ronald Muhlenkamp 176,385 sh (-0.27%)
Diamond Hill Capital 235,205 sh (-4.53%)
Vanguard Health Care Fund 4,923,200 sh (-8.19%)
Michael Price 447,500 sh (-10.50%)
NWQ Managers 4,011,187 sh (-14.62%)
John Keeley 37,955 sh (-20.45%)
George Soros 4,859,966 sh (-22.01%)
David Dreman 119,838 sh (-23.89%)
» More
Q1 2015

TEVA Guru Trades in Q1 2015

Andreas Halvorsen 228,600 sh (New)
Stanley Druckenmiller 790,500 sh (New)
Paul Tudor Jones 550,000 sh (New)
First Eagle Investment 4,205,481 sh (+71.77%)
Jim Simons 1,338,963 sh (+38.80%)
Pioneer Investments 1,147,578 sh (+10.80%)
Manning & Napier Advisors, Inc 311,423 sh (+6.26%)
Ronald Muhlenkamp 176,710 sh (+0.18%)
Charles Brandes 3,600 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Caxton Associates Sold Out
George Soros Sold Out
Louis Moore Bacon Sold Out
Michael Price 440,300 sh (-1.61%)
Richard Snow 1,807,419 sh (-2.66%)
John Keeley 36,835 sh (-2.95%)
James Barrow 10,189,904 sh (-5.85%)
NWQ Managers 3,669,079 sh (-8.53%)
Diamond Hill Capital 199,641 sh (-15.12%)
David Dreman 100,133 sh (-16.44%)
Vanguard Health Care Fund 1,896,960 sh (-61.47%)
Steven Cohen 91,000 sh (-61.76%)
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd - Mar 27, 2015

We trimmed into strength our position in Teva (TEVA), an Israel-based global biopharmaceutical company specializing in generic formulations. The stock rose substantially on a combination of speculation around M&A in the sector, enthusiasm for the new CEO, and the strong conversion of once-daily Copaxone to the three-times-a-week version.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd - Jun 26, 2014

Generic drug manufacturer Teva Pharmaceutical Industries Ltd. (TEVA) benefitted from the addition of a well-respected CEO and the continued successful transition of patients to a new, patent-protected version of the company’s multiple sclerosis drug.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

Paul Tudor Jones Buys Stakes in ADP and Visa
Paul Tudor Jones (Trades, Portfolio), founder of Tudor Investment Corporation, has been estimated to be worth in excess of $4 billion. Much of his money was made when he predicted “Black Monday” in October 1987, thanks to large short positions. Read more...
Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd
We trimmed into strength our position in Teva (TEVA), an Israel-based global biopharmaceutical company specializing in generic formulations. The stock rose substantially on a combination of speculation around M&A in the sector, enthusiasm for the new CEO, and the strong conversion of once-daily Copaxone to the three-times-a-week version. Read more...
The Gurus’ Favorite Asian Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Asian countries were held by the highest number of gurus. The following five companies come from a variety of industries, are Asian-based and are held by the largest number of gurus. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 19.22
TEVA's P/E(ttm) is ranked higher than
75% of the 469 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.80 vs. TEVA: 19.22 )
Ranked among companies with meaningful P/E(ttm) only.
TEVA' s 10-Year P/E(ttm) Range
Min: 10.53  Med: 20.27 Max: 1072.29
Current: 19.22
10.53
1072.29
Forward P/E 12.03
TEVA's Forward P/E is ranked higher than
89% of the 244 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. TEVA: 12.03 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.40
TEVA's PE(NRI) is ranked higher than
75% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.50 vs. TEVA: 18.40 )
Ranked among companies with meaningful PE(NRI) only.
TEVA' s 10-Year PE(NRI) Range
Min: 10.53  Med: 20.38 Max: 938.25
Current: 18.4
10.53
938.25
P/B 2.31
TEVA's P/B is ranked higher than
69% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. TEVA: 2.31 )
Ranked among companies with meaningful P/B only.
TEVA' s 10-Year P/B Range
Min: 1.37  Med: 2.32 Max: 4.88
Current: 2.31
1.37
4.88
P/S 2.61
TEVA's P/S is ranked higher than
63% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. TEVA: 2.61 )
Ranked among companies with meaningful P/S only.
TEVA' s 10-Year P/S Range
Min: 1.58  Med: 3.21 Max: 5.86
Current: 2.61
1.58
5.86
PFCF 15.01
TEVA's PFCF is ranked higher than
87% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.65 vs. TEVA: 15.01 )
Ranked among companies with meaningful PFCF only.
TEVA' s 10-Year PFCF Range
Min: 8.45  Med: 17.36 Max: 32.92
Current: 15.01
8.45
32.92
POCF 9.50
TEVA's POCF is ranked higher than
89% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.21 vs. TEVA: 9.50 )
Ranked among companies with meaningful POCF only.
TEVA' s 10-Year POCF Range
Min: 6.56  Med: 12.95 Max: 23.31
Current: 9.5
6.56
23.31
EV-to-EBIT 15.58
TEVA's EV-to-EBIT is ranked higher than
68% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.91 vs. TEVA: 15.58 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVA' s 10-Year EV-to-EBIT Range
Min: 12  Med: 20.40 Max: 991
Current: 15.58
12
991
PEG 3.91
TEVA's PEG is ranked lower than
60% of the 245 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. TEVA: 3.91 )
Ranked among companies with meaningful PEG only.
TEVA' s 10-Year PEG Range
Min: 0.38  Med: 1.39 Max: 174.07
Current: 3.91
0.38
174.07
Shiller P/E 21.72
TEVA's Shiller P/E is ranked higher than
77% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.23 vs. TEVA: 21.72 )
Ranked among companies with meaningful Shiller P/E only.
TEVA' s 10-Year Shiller P/E Range
Min: 14.08  Med: 33.91 Max: 75
Current: 21.72
14.08
75
Current Ratio 1.26
TEVA's Current Ratio is ranked lower than
81% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. TEVA: 1.26 )
Ranked among companies with meaningful Current Ratio only.
TEVA' s 10-Year Current Ratio Range
Min: 1.04  Med: 1.60 Max: 2.95
Current: 1.26
1.04
2.95
Quick Ratio 0.93
TEVA's Quick Ratio is ranked lower than
79% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. TEVA: 0.93 )
Ranked among companies with meaningful Quick Ratio only.
TEVA' s 10-Year Quick Ratio Range
Min: 0.68  Med: 1.10 Max: 2.19
Current: 0.93
0.68
2.19
Days Inventory 185.78
TEVA's Days Inventory is ranked lower than
78% of the 616 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.37 vs. TEVA: 185.78 )
Ranked among companies with meaningful Days Inventory only.
TEVA' s 10-Year Days Inventory Range
Min: 131.65  Med: 184.18 Max: 208.14
Current: 185.78
131.65
208.14
Days Sales Outstanding 99.27
TEVA's Days Sales Outstanding is ranked lower than
69% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.51 vs. TEVA: 99.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVA' s 10-Year Days Sales Outstanding Range
Min: 95.91  Med: 118.61 Max: 153.21
Current: 99.27
95.91
153.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.20
TEVA's Dividend Yield is ranked higher than
74% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. TEVA: 2.20 )
Ranked among companies with meaningful Dividend Yield only.
TEVA' s 10-Year Dividend Yield Range
Min: 0.34  Med: 0.95 Max: 3.26
Current: 2.2
0.34
3.26
Dividend Payout 0.43
TEVA's Dividend Payout is ranked higher than
74% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.31 vs. TEVA: 0.43 )
Ranked among companies with meaningful Dividend Payout only.
TEVA' s 10-Year Dividend Payout Range
Min: 0.04  Med: 0.13 Max: 5
Current: 0.43
0.04
5
Dividend growth (3y) 15.30
TEVA's Dividend growth (3y) is ranked higher than
70% of the 246 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. TEVA: 15.30 )
Ranked among companies with meaningful Dividend growth (3y) only.
TEVA' s 10-Year Dividend growth (3y) Range
Min: -6.7  Med: 27.00 Max: 80.9
Current: 15.3
-6.7
80.9
Yield on cost (5-Year) 6.24
TEVA's Yield on cost (5-Year) is ranked higher than
94% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.34 vs. TEVA: 6.24 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TEVA' s 10-Year Yield on cost (5-Year) Range
Min: 0.97  Med: 2.70 Max: 9.25
Current: 6.24
0.97
9.25
Share Buyback Rate 1.30
TEVA's Share Buyback Rate is ranked higher than
88% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.40 vs. TEVA: 1.30 )
Ranked among companies with meaningful Share Buyback Rate only.
TEVA' s 10-Year Share Buyback Rate Range
Min: 2.6  Med: -3.60 Max: -10.9
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.05
TEVA's Price/Projected FCF is ranked higher than
87% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. TEVA: 1.05 )
Ranked among companies with meaningful Price/Projected FCF only.
TEVA' s 10-Year Price/Projected FCF Range
Min: 0.6  Med: 1.56 Max: 29.17
Current: 1.05
0.6
29.17
Price/DCF (Earnings Based) 0.89
TEVA's Price/DCF (Earnings Based) is ranked higher than
86% of the 51 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. TEVA: 0.89 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.81
TEVA's Price/Median PS Value is ranked higher than
86% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. TEVA: 0.81 )
Ranked among companies with meaningful Price/Median PS Value only.
TEVA' s 10-Year Price/Median PS Value Range
Min: 0.5  Med: 1.05 Max: 1.8
Current: 0.81
0.5
1.8
Earnings Yield (Greenblatt) (%) 6.14
TEVA's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. TEVA: 6.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEVA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 4.90 Max: 8.4
Current: 6.14
0.1
8.4
Forward Rate of Return (Yacktman) (%) 10.38
TEVA's Forward Rate of Return (Yacktman) (%) is ranked higher than
58% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. TEVA: 10.38 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TEVA' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 7.7  Med: 19.80 Max: 51.2
Current: 10.38
7.7
51.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, AGN, FRX, MRX, ESALF » details
Traded in other countries:TEVAN.Mexico, TEV.Germany, TEVA.Switzerland, TEVA.Israel, TEVJF.USA,
Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments such as generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as API business; and specialty products, which includes several core franchises, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. In addition to these two segments, the Company has other activities, primarily PGT Healthcare, OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. The Company, along with its subsidiaries operates in approximately 60 countries. It develops, manufactures and sell generic pharmaceutical products in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. Specialty medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, includes several core therapeutic areas, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. Some of its products are Copaxone, Azilect & Provigil, among others. The Company markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").
» More Articles for TEVA

Headlines

Articles On GuruFocus.com
Paul Tudor Jones Buys Stakes in ADP and Visa Jun 19 2015 
KEELEY All Cap Value Fund First Quarter 2015 Commentary Jun 17 2015 
Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks Jun 11 2015 
Leon Cooperman's Top Holdings Look Attractive Jun 09 2015 
Actavis Stock – A Must Have For Long-Term Investors May 27 2015 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
Stanley Druckenmiller's Top 5 New Stocks May 25 2015 
Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 
Teva Eyeing Mylan For $40 Billion Apr 23 2015 
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 

More From Other Websites
Teva, Xenon Pain Drug Fails Phase IIb Study, Xenon Slumps - Analyst Blog Jul 02 2015
Teva-Xenon Arthritis Pain Drug Fails Midstage Trial Jul 01 2015
Top Takeaways From BMO's Specialty Pharma Day Jul 01 2015
Teva Launches Generic Aggrenox® Capsules in the United States Jul 01 2015
Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain Jul 01 2015
Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain Jul 01 2015
Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain Jul 01 2015
A New Rider in the Perrigo, Mylan, Teva Merger Merry-Go-Round Jun 30 2015
Unusual Covered Call Opportunity Teva Pharmaceuticals Jun 30 2015
Pharma bulls like Teva, Horizon Jun 30 2015
Cash is not Always King in Pharma Pay-to-Delay Deals: Appeals Court Jun 26 2015
Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO... Jun 25 2015
Short Sellers Become More Focused on Big Pharma Jun 25 2015
Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO... Jun 25 2015
Alder Bio Up As Credit Suisse Lauds Migraine Drug Jun 24 2015
Teva Launches PainMatters.com to Support Responsible Pain Management Jun 24 2015
Healthcare-Focused Fund Camber Capital’s Top Picks: Masimo Corporation (MASI), The Medicines... Jun 23 2015
Mylan CFO to meet Tel Aviv bourse chief to discuss listing - source Jun 23 2015
Eagle Pharma Has 'Several Upcoming Catalysts' And Is A Buy, RBC Says Jun 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK